Literature DB >> 17137841

Anti-IgA antibodies in common variable immunodeficiency (CVID): diagnostic workup and therapeutic strategy.

Julia Horn1, Vojtech Thon, Dana Bartonkova, Ulrich Salzer, Klaus Warnatz, Michael Schlesier, Hans-Hartmut Peter, Bodo Grimbacher.   

Abstract

Common Variable Immunodeficiency (CVID) patients who are seropositive for anti-IgA antibodies have a predisposition for anaphylactoid reactions to intravenous immunoglobulin replacement therapy (IVIG). Among 88 CVID patients, we identified eight with IgG anti-IgA antibodies (9%). All eight completely lacked IgA (<0.0009 g/l). Five of them had a history of anaphylactoid reactions to IVIG. However, four of these five patients tolerated subcutaneous immunoglobulin replacement therapy (SCIG). To identify predisposing factors for anti-IgA antibodies and related anaphylactoid reactions, we analyzed the clinical and immunological phenotype of affected patients. All eight IgG anti-IgA-positive patients lacked IgA(+) B cells in peripheral blood. Moreover, CVID patients with retained class-switched CD27(pos) IgM(neg) IgD(neg) memory B cells (Freiburg classification group II) and total IgA deficiency seem to have an increased risk for developing anti-IgA antibodies. In seven of the eight patients, lymphoproliferation was observed (most prominently nodular lymphatic hyperplasia), two had granulomatous disease, and two showed autoimmune phenomena.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17137841     DOI: 10.1016/j.clim.2006.10.002

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   3.969


  14 in total

1.  Immune globulin subcutaneous (human), 20% liquid.

Authors: 
Journal:  P T       Date:  2010-08

2.  International Consensus Document (ICON): Common Variable Immunodeficiency Disorders.

Authors:  Francisco A Bonilla; Isil Barlan; Helen Chapel; Beatriz T Costa-Carvalho; Charlotte Cunningham-Rundles; M Teresa de la Morena; Francisco J Espinosa-Rosales; Lennart Hammarström; Shigeaki Nonoyama; Isabella Quinti; John M Routes; Mimi L K Tang; Klaus Warnatz
Journal:  J Allergy Clin Immunol Pract       Date:  2015-11-07

3.  Prospective study on CVID patients with adverse reactions to intravenous or subcutaneous IgG administration.

Authors:  Isabella Quinti; Annarosa Soresina; Carlo Agostini; Giuseppe Spadaro; Andrea Matucci; Ifigeneia Sfika; Helene Martini; Federica Borghese; Andrea Guerra; Vultaggio Alessandra; Marcella Visentini; Alessandro Plebani; Massimo Fiorilli
Journal:  J Clin Immunol       Date:  2008-05       Impact factor: 8.317

4.  9 Human Immunoglobulins.

Authors: 
Journal:  Transfus Med Hemother       Date:  2009       Impact factor: 3.747

Review 5.  Intravenous immunoglobulin in neurology--mode of action and clinical efficacy.

Authors:  Jan D Lünemann; Falk Nimmerjahn; Marinos C Dalakas
Journal:  Nat Rev Neurol       Date:  2015-01-06       Impact factor: 42.937

Review 6.  Home-based subcutaneous immunoglobulin versus hospital-based intravenous immunoglobulin in treatment of primary antibody deficiencies: systematic review and meta analysis.

Authors:  Hassan Abolhassani; Mohammad Salehi Sadaghiani; Asghar Aghamohammadi; Hans D Ochs; Nima Rezaei
Journal:  J Clin Immunol       Date:  2012-06-23       Impact factor: 8.317

Review 7.  Subcutaneous immunoglobulins in the treatment of chronic immune-mediated neuropathies.

Authors:  Verena I Leussink; Hans-Peter Hartung; Bernd C Kieseier; Mark Stettner
Journal:  Ther Adv Neurol Disord       Date:  2016-04-06       Impact factor: 6.570

8.  Long-Term Treatment and Transfusion of Normal Blood Components Following Tolerance Induction in Patients with Anti-IgA Anaphylactic Reactions.

Authors:  Abdulgabar Salama; Romina Kardashi; Olga Arbach
Journal:  Transfus Med Hemother       Date:  2014-09-15       Impact factor: 3.747

Review 9.  Treatment of Juvenile Dermatomyositis: An Update.

Authors:  Charalampia Papadopoulou; Lucy R Wedderburn
Journal:  Paediatr Drugs       Date:  2017-10       Impact factor: 3.022

10.  Neutralizing antibodies to therapeutic enzymes: considerations for testing, prevention and treatment.

Authors:  Jinhai Wang; Jay Lozier; Gibbes Johnson; Susan Kirshner; Daniela Verthelyi; Anne Pariser; Elizabeth Shores; Amy Rosenberg
Journal:  Nat Biotechnol       Date:  2008-08       Impact factor: 54.908

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.